Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 13/20 | 0.53 |
| ▸ | DHODH | Q02127 | 2/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372595 | 0.88 | SMN1; SMN2 (0.54) | TACR3DHODHSMN1; SMN2MEN1KMT2A | |
| SCHEMBL2373281 | 0.87 | KDM4E (0.55) | TACR3DHODHPLA2G2ASMN1; SMN2MEN1 | |
| SCHEMBL2372559 | 0.86 | TRPV4 (0.50) | TACR3DHODHSMN1; SMN2 | |
| SCHEMBL5482733 | 0.86 | TACR3 (0.53) | TACR3DHODHPLA2G2ASMN1; SMN2 | |
| SCHEMBL4879045 | 0.85 | DHODH (0.71) | TACR3DHODHSMN1; SMN2MEN1KMT2A | |
| SCHEMBL15491395 | 0.84 | TACR3 (0.68) | TACR3DHODH | |
| SCHEMBL5481030 | 0.82 | TACR3 (0.49) | TACR3DHODHPLA2G2A | |
| SCHEMBL4895783 | 0.80 | BDKRB1 (0.50) | TACR3DHODHPLA2G2A | |
| SCHEMBL27729454 | 0.79 | LMNA (0.53) | TACR3DHODHSMN1; SMN2MEN1KMT2A | |
| SCHEMBL4875432 | 0.79 | KDM4E (0.49) | TACR3SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
| EP-1891012-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| EP-1812398-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SmithKline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2007-06-21 | — | — | US | disclosed |
| WO-2006130080-A2 | QUINOLINE DERIVATIVES AS NK3 ANATGONISTS | ASTRAZENECA AB (SE) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006050991-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006050992-A1 | COMPOUNDS HAVING ACTIVITY AT NK3 RECEPTOR AND USES THEREOF IN MEDICINE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| EP-1651632-A1 | QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014575-A1 | QUINOLINE 4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS NEUROKININ 3 (NK-3) RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142431-A1 | Quinoline 4-carboxamide derivatives and their use as neurokinin 3 (nk-3) receptor antagonists | TACR3, GRIK3, TACR2 | TACR3 1/4885DHODH 3942/4885PLA2G2A 3634/4885 |
| US-20080261945-A1 | Compounds Having Activity at Nk3 Receptor and Uses Thereof in Medicine | CNR1, ACKR3, HCAR3 | TACR3 41/4885DHODH 3421/4885PLA2G2A 3899/4885 |
| US-20080200500-A1 | Quinoline Derivatives as Nk3 Antagonists | KCNQ3, KCNA3, KCNK3 | TACR3 17/4885DHODH 2651/4885PLA2G2A 3344/4885 |
| US-20080103173-A1 | Compounds Having Activity At Nk3 Receptor And Uses Thereof In Medicine | TACR1, TACR2, KCNA3 | TACR3 10/4885DHODH 3143/4885PLA2G2A 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.